- Currency Conversion is for Indicative purpose only. All orders are processed in US Dollars only.
- USD - US Dollar
- AUD — Australian Dollar
- BRL — Brazilian Real
- CNY — Yuan Renminbi
- EUR — Euro
- GBP — Pound Sterling
- INR — Indian Rupee
- JPY — Japanese Yen
- ZAR — South African Rand
- The Price Conversion is only for the Indicative purpose.
- USD — US Dollar
- AUD — Australian Dollar
- BRL — Brazilian Real
- CNY — Yuan Renminbi
- EUR — Euro
- GBP — Pound Sterling
- INR — Indian Rupee
- JPY — Japanese Yen
- ZAR — South African Rand
-
Sector Analysis
Sector Analysis PharmaPoint: Dyslipidemia – Global Drug Forecast and Market Analysis to 2025 PharmaPoint: Dyslipidemia – Global Drug Forecast and Market Analysis to 2025
$10,995 | December 2016 GlobalData estimates sales of dyslipidemia therapeutics to be approximately $11.2B across the 7MM in 2015, encompassing the US, 5EU, and Japan. The dyslipidemia market will grow at a strong CAGR of 10.1% over the forecast period, reaching sales of $29.2B by 2025. The US is the largest market for dyslipidemia therapies, contributing approximately 61.5% of total sales in the base year. GlobalData expects uptake of the revolutionary class of PCSK9 targeting biologics to be the strongest driver of growth in...
-
Product Insights
Product Insights Familial Chylomicronemia (Type I Hyperlipoproteinemia) Global Clinical Trials Review, H1, 2016 Familial Chylomicronemia (Type I Hyperlipoproteinemia) Global Clinical Trials Review, H1, 2016
$2,500 | June 2016 GlobalData's clinical trial report, “Familial Chylomicronemia (Type I Hyperlipoproteinemia) Global Clinical Trials Review, H1, 2016" provides an overview of Familial Chylomicronemia (Type I Hyperlipoproteinemia) clinical trials scenario. This report provides top line data relating to the clinical trials on Familial Chylomicronemia (Type I Hyperlipoproteinemia). Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end...
Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.